🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 65 of 116

  1. Part 1: VP-315 3 Day Dosing/Week

    Verrica Pharmaceuticals

    Basal Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  2. Patritumab deruxtecan

    Daiichi Sankyo

    Metastatic or Locally Advanced EGFR mutated Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  3. Patritumab deruxtecan

    Daiichi Sankyo

    Locally Advanced or Metastatic Solid Tumors

    phase 2 small molecule active

    1 trial

  4. Patupilone

    Novartis Pharmaceuticals

    Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial

  5. Paxalisib

    KAZIA THERAPEUTICS LTD

    Childhood Cancer

    phase 2 small molecule active

    1 trial

  6. Pedmark® STS

    FENNEC PHARMACEUTICALS INC.

    Solid Tumor Malignancies

    phase 2 small molecule active

    1 trial

  7. Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) regimen

    The First People's Hospital of Lianyungang

    NK-T-Cell Lymphoma, Extranodal

    phase 2 small molecule active

    1 trial

  8. Pegvorhyaluronidase alfa

    HALOZYME THERAPEUTICS, INC.

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule terminated

    1 trial

  9. Pegylated Irinotecan

    Nektar Therapeutics UK Limited

    Stage IV Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule completed

    1 trial

  10. Pegylated Irinotecan

    Nektar Therapeutics UK Limited

    Recurrent Small Cell Lung Carcinoma

    phase 2 small molecule completed

    1 trial

  11. Pelareorep

    ONCOLYTICS BIOTECH INC

    Anatomic Stage IV Breast Cancer AJCC v8

    phase 2 mab active

    1 trial

  12. Pelareorep

    ONCOLYTICS BIOTECH INC

    Anal Cancer Metastatic

    phase 2 small molecule active

    1 trial

  13. Pemazyre 4.5 mg tablets

    The George Institute

    locally advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements

    phase 2 small molecule active

    1 trial

  14. Pemazyre 4.5 mg tablets

    Ningbo Cancer Hospital

    Recurrent or metastatic solid cancer harboring a FGFR1,2 ,3 fusion/rearrangement or activating mutation, outside of the approved indications for any selective FGFR inhibitor in France

    phase 2 small molecule active

    1 trial

  15. Pemazyre 4.5 mg tablets, INCAGN02385, INCAGN02390, Retifanlimab (INCMGA00012)

    Incyte

    Endometrial cancer, Endometrial cancer

    phase 2 small molecule active

    1 trial

  16. Pembrolizumab

    Syndax Pharmaceuticals

    Bladder Cancer

    phase 2 small molecule active

    1 trial

  17. Pembrolizumab

    Genmab A/S

    Advanced Endometrial Cancer

    phase 2 mab terminated

    1 trial

  18. Pembrolizumab

    Syndax Pharmaceuticals

    Metastatic Uveal Melanoma

    phase 2 small molecule completed

    1 trial

  19. Pembrolizumab

    IO Biotech

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  20. Pembrolizumab

    United Therapeutics Europe Ltd

    Metastatic Small Intestinal Adenocarcinoma

    phase 2 mab active

    1 trial

  21. Pembrolizumab

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 small molecule active

    1 trial

  22. Pembrolizumab

    United Therapeutics Europe Ltd

    Castration-resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  23. Pembrolizumab

    United Therapeutics Europe Ltd

    Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  24. Pembrolizumab

    United Therapeutics Europe Ltd

    Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  25. Pembrolizumab

    TG THERAPEUTICS, INC.

    Hodgkin's Lymphoma

    phase 2 mab terminated

    1 trial

  26. Pembrolizumab

    Bicara Therapeutics

    Head and Neck Squamous Cell Carcinoma

    phase 2 mab active

    1 trial

  27. Pembrolizumab

    Inhibrx Biosciences

    Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  28. Pembrolizumab

    ALX ONCOLOGY HOLDINGS INC

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  29. Pembrolizumab

    Incyte

    Lung Cancer

    phase 2 small molecule completed

    2 trials

  30. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Melanoma

    phase 2 mab completed

    1 trial

  31. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Advanced Non-Small Cell Lung Cancer

    phase 2 mab completed

    1 trial

  32. Pembrolizumab

    Karyopharm Therapeutics Inc

    Advanced Urothelial Carcinoma

    phase 2 mab terminated

    1 trial

  33. Pembrolizumab (+) Berahyaluronidase alfa

    Merck KGaA, Darmstadt, Germany

    Squamous Cell Carcinoma

    phase 2 mab active

    1 trial

  34. Pembrolizumab (200mg IV for 30 minutes

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 small molecule active

    1 trial

  35. Pembrolizumab (KEYTRUDA®) and PDS0101

    PDS Biotechnology Corp

    Metastatic Head and Neck Cancer

    phase 2 other completed

    1 trial

  36. Pembrolizumab 200 mg

    Merck KGaA, Darmstadt, Germany

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 mab active

    1 trial

  37. Pembrolizumab 200 mg

    Merck KGaA, Darmstadt, Germany

    Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  38. Pembrolizumab 200 mg IV infusion

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stage IIIB(N2) Non-small Cell Lung Cancer

    phase 2 mab active

    1 trial

  39. Pembrolizumab Injection

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  40. Pembrolizumab plus denosumab

    Zealand Pharma A/S

    Renal Cell Carcinoma, Clear Cell

    phase 2 small molecule active

    1 trial

  41. Pembrolizumab/Vibostolimab coformulation

    Merck KGaA, Darmstadt, Germany

    Metastatic Non Small Cell Lung Cancer

    phase 2 mab completed

    1 trial

  42. Pemebit

    Hospital Authority, Hong Kong

    Adenocarcinoma

    phase 2 small molecule completed

    1 trial

  43. Pemetrexe

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Central Nervous System Tumors

    phase 2 small molecule active

    1 trial

  44. Pemetrexed

    Mereo BioPharma Group plc

    Nonsquamous Nonsmall Cell Neoplasm of Lung

    phase 2 small molecule completed

    1 trial

  45. Pemetrexed

    The First People's Hospital of Lianyungang

    Colorectal Neoplasms

    phase 2 small molecule active

    1 trial

  46. Pemetrexed

    Samsung Bioepis NL B.V.

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  47. Pemetrexed EVER Pharma 25 mg/ml concentrate for solution for infusion, Carboplatino Aurovitas 10 mg/ml concentrado para solución para perfusión EFG, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Pemetrexed Glenmark 10 mg/ml solución para perfusión, Carboplatino Hikma 10 mg/ml soluzione per infusione, OMTX705, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Carboplatino Teva 10 mg/ml Concentrado para solución para perfusión, Carboplatino Accord 10 mg/ml concentrado para

    Lacuna Pharma Pty Ltd

    Advanced/Metastatic Non-squamous Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  48. Pemetrexed Ever Pharma 25 mg/ml concentrato per soluzione per infusione, JNJ-61186372

    Fondazione Telethon ETS

    Non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.